---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009622"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:37:23.518340+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio Q1 net loss $16.7M, cash $58.8M; MB-106 trial data expected Q2

## Summary
- Cash and cash equivalents $58.8M at Mar 31, 2023, down $17.9M from Dec 31, 2022.
- Net loss $16.7M ($2.06/share) vs $19.8M ($2.71/share) in Q1 2022; R&D expenses $14.0M.
- MB-106 (CD20 CAR T) shows 96% ORR and 75% CR in Fred Hutch trial; multicenter trial accruing.
- Orphan Drug Designation for MB-106 in Waldenstrom macroglobulinemia; pivotal Phase 2 may start Q1 2024.
- In April 2023, executed 15-for-1 reverse stock split and repaid $30.7M loan to Runway.

## SEC filing metadata
- accession: 0001558370-23-009622
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023009622/0001558370-23-009622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023009622/tmb-20230512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009622
- JSON: https://secwatch.observer/filing/0001558370-23-009622.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009622.txt

## Key facts
- Earnings Releases
  MUSTANG BIO, INC. reported the first quarter ended March 31, 2023 results: net income Net loss attributable to common stockholders was $16.7 million, or $2.06 per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: Net loss attributable to common stockholders was $16.7 million, or $2.06 per share
  - Result: reported results
  source text: On May 12, 2023, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680048/000155837023009622/0001558370-23-009622-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.